Kyung Nam Pharm Co Ltd (053950) - Net Assets
Based on the latest financial reports, Kyung Nam Pharm Co Ltd (053950) has net assets worth ₩117.50 Billion KRW (≈ $79.63 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩143.23 Billion ≈ $97.06 Million USD) and total liabilities (₩25.73 Billion ≈ $17.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Kyung Nam Pharm Co Ltd (053950) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩117.50 Billion |
| % of Total Assets | 82.04% |
| Annual Growth Rate | 11.67% |
| 5-Year Change | 88.79% |
| 10-Year Change | 272.13% |
| Growth Volatility | 41.85 |
Kyung Nam Pharm Co Ltd - Net Assets Trend (2007–2025)
This chart illustrates how Kyung Nam Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Kyung Nam Pharm Co Ltd.
Annual Net Assets for Kyung Nam Pharm Co Ltd (2007–2025)
The table below shows the annual net assets of Kyung Nam Pharm Co Ltd from 2007 to 2025. Also explore Kyung Nam Pharm Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩108.30 Billion ≈ $73.39 Million |
-6.01% |
| 2024-12-31 | ₩115.22 Billion ≈ $78.09 Million |
+28.26% |
| 2023-12-31 | ₩89.83 Billion ≈ $60.88 Million |
-4.20% |
| 2022-12-31 | ₩93.77 Billion ≈ $63.55 Million |
+63.47% |
| 2020-12-31 | ₩57.36 Billion ≈ $38.87 Million |
-6.26% |
| 2019-12-31 | ₩61.19 Billion ≈ $41.47 Million |
+111.66% |
| 2018-12-31 | ₩28.91 Billion ≈ $19.59 Million |
+71.88% |
| 2016-12-31 | ₩16.82 Billion ≈ $11.40 Million |
-23.45% |
| 2010-12-31 | ₩21.97 Billion ≈ $14.89 Million |
-24.50% |
| 2009-12-31 | ₩29.10 Billion ≈ $19.72 Million |
+35.04% |
| 2008-12-31 | ₩21.55 Billion ≈ $14.60 Million |
+45.11% |
| 2007-12-31 | ₩14.85 Billion ≈ $10.06 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Kyung Nam Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 85642.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩138.46 Billion | 127.85% |
| Total Equity | ₩108.30 Billion | 100.00% |
Kyung Nam Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Kyung Nam Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SRAX Inc
NASDAQ:SRAX
|
$14.72K |
|
CRESTVIEW EXPLORATION INC
F:CE7
|
$14.74K |
|
Tirupati Graphite plc
LSE:TGR
|
$14.85K |
|
Distil Plc
LSE:DIS
|
$14.85K |
|
Hana Microelectronics Public Company Limited
F:HAA1
|
$14.42K |
|
Eos Energy Enterprises Inc
NASDAQ:EOSEW
|
$14.31K |
|
Cloudcoco Group PLC
LSE:CLCO
|
$14.18K |
|
KRUNG THAI -FGN- BA 515
F:KTB1
|
$14.16K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kyung Nam Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 115,223,111,870 to 108,299,757,880, a change of -6,923,353,990 (-6.0%).
- Net loss of 9,006,666,810 reduced equity.
- Other factors increased equity by 2,083,312,820.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-9.01 Billion | -8.32% |
| Other Changes | ₩2.08 Billion | +1.92% |
| Total Change | ₩- | -6.01% |
Book Value vs Market Value Analysis
This analysis compares Kyung Nam Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.37x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.23x to 0.37x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩9811.45 | ₩2280.00 | x |
| 2023-12-31 | ₩7810.68 | ₩2280.00 | x |
| 2024-12-31 | ₩6604.13 | ₩2280.00 | x |
| 2025-12-31 | ₩6207.31 | ₩2280.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kyung Nam Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.10%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.44x
- Recent ROE (-8.32%) is below the historical average (-3.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 6.74% | 1.93% | 0.79x | 4.41x | ₩-481.15 Million |
| 2016 | 0.77% | 0.33% | 0.88x | 2.69x | ₩-1.55 Billion |
| 2018 | 12.87% | 8.98% | 0.78x | 1.84x | ₩829.00 Million |
| 2019 | -7.43% | -10.15% | 0.60x | 1.22x | ₩-10.67 Billion |
| 2020 | -9.57% | -7.73% | 0.56x | 2.21x | ₩-11.22 Billion |
| 2022 | -8.35% | -13.27% | 0.43x | 1.47x | ₩-17.21 Billion |
| 2023 | -26.46% | -35.41% | 0.36x | 2.10x | ₩-28.93 Billion |
| 2024 | 8.75% | 16.58% | 0.36x | 1.45x | ₩-1.45 Billion |
| 2025 | -8.32% | -16.10% | 0.36x | 1.44x | ₩-19.84 Billion |
Industry Comparison
This section compares Kyung Nam Pharm Co Ltd's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kyung Nam Pharm Co Ltd (053950) | ₩117.50 Billion | 6.74% | 0.22x | $14.62K |
| Samyang Holdings Corp (000075) | $3.00 Trillion | 0.94% | 0.76x | $17.20 Million |
| POBIS TNC CO. Ltd (016670) | $86.07 Billion | 12.91% | 0.50x | $58.05 Million |
| Posco ICT Company Ltd (022100) | $388.01 Billion | 6.61% | 1.12x | $2.80 Billion |
| Osung Advanced Materials Co. Ltd (052420) | $194.40 Billion | 5.26% | 0.32x | $363.11 Million |
| ilShinbiobase Co. Ltd (068330) | $35.22 Billion | 5.98% | 0.09x | $29.84 Million |
| Kuk-Il Paper Mfg Co.Ltd (078130) | $17.91 Billion | 0.00% | 3.60x | $294.00 Million |
| OncoQuest Pharmaceuticals Inc (078590) | $48.94 Billion | -22.72% | 0.67x | $105.53 Million |
| MCNEX Co. Ltd (097520) | $98.02 Billion | -0.91% | 2.96x | $328.51 Million |
| Smac Co. Ltd (097780) | $265.49 Billion | 5.87% | 0.26x | $224.21 Million |
About Kyung Nam Pharm Co Ltd
Kyung Nam Pharm Co.,Ltd. manufactures pharmaceuticals. The company offers over-the-counter products, including antipyretics, analgesics, and antiphlogistics; medications for skin diseases and athlete's foot; pain relief patches/creams, antitussives, mucolytic agents, and expectorants; gastro protective agents/digestives; periodontal/gum disease drugs; medications for liver diseases; ear and nose … Read more